With major changes ahead for EU Health Technology Assessments (HTAs), including the introduction of joint clinical assessments from 2025, developers must adapt quickly to new regulatory expectations.
In a recent article for PharmaPhorum, Stephen Corson, Associate Director, Statistics and Technical Solutions and Head of Statistical Consultancy at Phastar, outlines how developers can prepare for the evolving HTA landscape — highlighting key challenges, strategic solutions, and the importance of early planning and stakeholder alignment to ensure successful market access.
”By proactively planning and ensuring clear communication between stakeholders, developers can successfully navigate this regulatory shift and seize opportunities in the evolving HTA landscape, which looks likely to set a new standard for health technology assessment.”